RT Journal Article
SR Electronic
T1 Primary lung cancer treated using radiofrequency ablation - One year outcome data
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 3268
VO 40
IS Suppl 56
A1 Faisal Kamal
A1 Julie Beeson
A1 Sunny Kaul
A1 Sarah Stirling
A1 Simon Mattison
A1 Juliette Tennant
A1 Pasha Normahani
A1 Paras Dalal
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/3268.abstract
AB BackgroundPercutaneous image guided radiofrequency ablation (RFA) is increasingly used as an alternative treatment option for patients with inoperable primary non small cell lung cancer (NSLC) but there are little published outcome data. We report safety & efficacy of RFA in patients with NSCLC (stages 1-4) at 1 year.Methods Thirty-eight patients underwent 50 RFA procedures.Complications, local progression & survival were evaluated prospectively at 3, 6, 9 & 12 months.Statistical analysis was performed using log rank test & Cox regression analysis to determine hazard ratios with 95% confidence intervals (CI).Kaplan-Meier survival curves were plotted to show any differences in the survival pattern using Stata 10.1 (Statacorp, Texas USA).ResultsThere were no cases of procedure related mortality.Complications included pneumothorax (61%) of which 10 patients (43%) had an iatrogenically created pneumothorax as part of the procedure, pleural effusion (5%) & respiratory failure (3%).At 1 year: new (suspicious) nodules observed in 21% (n=8), 88% of patients with tumours <3cm were progression free compared to 76.9% of tumours >3cm (p=0.36).Mean time to progression for all cases 11.4 months (CI 10.7-12.1).Tumours <3cm (n=25, 11.6 months, CI 11.1-12.3) versus tumours >3cm (n=13, 10.9 months, CI 9.0-12.7).Overall & cancer specific 1 year survival were 86.8% & 92.1% respectively.1 year survival for tumours <stage 4 (n=27) and those at stage 4 (n=11) were 89 % (n=24/27) and 63.6% (n= 7/11) respectively which did not reach statistical significance.ConclusionRFA is a safe, effective & well-tolerated treatment option in patients with inoperable primary lung cancer (stages 1-4).